Evaluation of the Effectiveness and Safety of the Ulthera® DeepSEE® System for Treating Skin Laxity in the Lower Face and Submentum

Merz Pharmaceuticals

Status

Completed

Conditions

Improvement in Skin Laxity of the Lower Face and Submentum

Treatments

Device: Untreated-control / delayed-treatment

Device: Ultherapy treatment

Study type

Interventional

Funder types

Industry

Identifiers

NCT04795622

M960101056

Details and patient eligibility

About

Demonstrate superiority of treatment with the Ulthera DeepSEE System compared to untreated control for the improvement of skin laxity of the lower face and submental area.
Demonstrate the safety of treatment with the Ulthera DeepSEE System for the improvement of skin laxity of the lower face and submental area.

Full description

Subjects in the study received a single treatment with Ulthera DeepSEE system on the midface, lower face, submental (under the chin) and upper neck area using 3 DeepSEE (DS) transducers (DS 10-1.5, DS 7-3.0, DS 7-4.5) at either Day 1 or Day 90. Subjects treated at Day 1 were followed for 180 days after treatment and subjects treated at Day 90 were followed for 90 days after treatment.

Enrollment

201 patients

Sex

All

Ages

35 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Mild to moderate lower face and/or submental laxity that is amenable to improvement with non-invasive intervention and is not severe enough for surgical intervention;

Exclusion criteria

Scarring in area(s) to be treated;
Any active implants (e.g., pacemakers or defibrillators) in the area(s) to be treated;
Any metallic implants in area(s) to be treated;
Any open wounds or lesions in the area(s) to be treated;
Body mass index (BMI) less than 19 or greater than 30; or
Gain or loss of ≥ 2 BMI units within the previous 90 days or has the intention to gain or lose ≥ 2 BMI units during the course of the trial.